glp-1 receptor agonist and dpp-4 inhibitor combination not recommended inhibitors for type 2 diabetes management Molecular Insights into the Potential

Hepatic cholesterol metabolism involves multiple parts, including cholesterol uptake, synthesis, biotransformation, and efflux

Int J Mol Sci 2022;23:14631.ArticlePubMedPMC 86

1416 Beyond compositional shifts, the functional consequences of dysbiosis are particularly relevant: the microbiota contributes to obesity pathophysiology by driving the production of short-chain fatty acids (SCFAs), modulating bile acid metabolism, and influencing immune and inflammatory pathways

GLP-1 receptor agonists are prescription medications regardless of dose

This is likely because GLP-1 agonists can delay the emptying of bile from the gallbladder

Because prospective endpoint studies comprising large patient populations had just been published for saxagliptin (The Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus [SAVOR]Thrombolysis in Myocardial Infarction [TIMI] 53 trial [SAVOR-TIMI 53]